Share Price and Basic Stock Data
Last Updated: December 26, 2025, 10:29 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Zota Health Care Ltd, operating in the pharmaceuticals sector, reported a current market capitalization of ₹5,097 Cr and a stock price of ₹1,537. The company has seen significant fluctuations in revenue, with sales rising from ₹131 Cr in FY 2022 to ₹139 Cr in FY 2023, and projected to increase to ₹180 Cr in FY 2024 and ₹292 Cr in FY 2025. The trailing twelve months (TTM) revenue stood at ₹402 Cr. Quarterly sales have shown an upward trend, with ₹45 Cr reported for September 2023 and ₹50 Cr for March 2024, indicating a recovery from prior declines. However, this growth is juxtaposed against a backdrop of rising expenses, which increased from ₹132 Cr in FY 2023 to a projected ₹298 Cr in FY 2025, underscoring challenges in maintaining profitability. The overall trajectory suggests potential for growth but raises questions about sustainability amid escalating costs.
Profitability and Efficiency Metrics
Zota Health Care’s profitability metrics reflect significant challenges, with a reported net profit of -₹62 Cr for FY 2025, following a loss of ₹14 Cr in FY 2024. The company’s operating profit margin (OPM) has fluctuated, with a negative OPM of -2% projected for FY 2025, down from 5% in FY 2023. This decline is alarming, particularly given the increasing sales figures. The interest coverage ratio (ICR) stood at -0.33x, indicating that the company is unable to cover its interest obligations through operating profits. The cash conversion cycle (CCC) has risen to 219 days, suggesting inefficiencies in working capital management. While return on equity (ROE) was at a commendable 36.0%, the return on capital employed (ROCE) fell to 17.0%, reflecting declining operational efficiency. These profitability and efficiency metrics highlight a critical need for strategic realignment to improve operational performance.
Balance Sheet Strength and Financial Ratios
Zota Health Care’s balance sheet shows a mixture of strengths and weaknesses. As of FY 2025, the company reported total borrowings of ₹181 Cr against reserves of ₹285 Cr, indicating a manageable debt level relative to its equity. The current ratio stood at 1.83, suggesting adequate liquidity to meet short-term obligations. However, the negative interest coverage ratio (ICR) of -0.33x raises concerns about the company’s ability to service its debt. The price-to-book value (P/BV) ratio is 10.31x, which is significantly high compared to typical sector norms, suggesting that the stock may be overvalued. Moreover, with a total asset value of ₹439 Cr, the company has shown growth in fixed assets, which stood at ₹185 Cr, indicating potential for future revenue generation. However, the increasing operational losses and high valuation pose risks that could impact investor sentiment.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Zota Health Care indicates a concentrated ownership structure, with promoters holding 55.81% of the shares as of September 2025. This is a decline from 68.12% in December 2022, which may suggest a gradual dilution of control. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 3.49% and 4.95%, respectively, indicating limited institutional interest compared to retail investors, who constitute 35.75% of the shareholder base. The total number of shareholders has increased to 11,855, reflecting growing retail participation. However, the declining promoter stake may raise concerns regarding long-term commitment and confidence in the company’s direction. As investor confidence is crucial for stock performance, the current shareholding dynamics may influence market perceptions, especially given the company’s ongoing financial challenges.
Outlook, Risks, and Final Insight
The outlook for Zota Health Care is marked by both potential and risk. On one hand, the company is positioned to benefit from increasing sales, with a projected growth trajectory towards ₹292 Cr in FY 2025. However, the persistent operational losses and declining profitability metrics raise significant concerns about sustainability. Key risks include high operational costs, which have outpaced revenue growth, and a deteriorating interest coverage ratio that suggests potential liquidity issues. Additionally, the declining promoter stake may impact market confidence. Moving forward, Zota Health Care must focus on enhancing operational efficiencies, managing costs effectively, and restoring profitability to regain investor trust. If the company can successfully navigate these challenges, it may unlock substantial growth opportunities; however, failure to address these issues could lead to further financial distress.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,105.46 Cr | 1,149.90 | 52.70 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39 | 35 | 37 | 39 | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 | 129 |
| Expenses | 34 | 35 | 36 | 37 | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 | 123 |
| Operating Profit | 5 | 0 | 1 | 1 | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 | 6 |
| OPM % | 12% | 0% | 3% | 3% | 10% | 7% | -3% | -2% | -1% | -8% | 3% | 4% | 5% |
| Other Income | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 |
| Depreciation | 3 | 3 | 4 | 3 | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 | 19 |
| Profit before tax | 2 | -3 | -3 | -3 | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 | -14 |
| Tax % | 58% | -4% | -15% | 1% | 49% | 7% | -27% | 5% | -4% | 2% | -10% | 5% | 13% |
| Net Profit | 1 | -3 | -3 | -3 | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 | -16 |
| EPS in Rs | 0.36 | -1.28 | -1.05 | -1.13 | -0.64 | -1.14 | -2.68 | -4.79 | -4.41 | -6.78 | -4.50 | -4.81 | -5.20 |
Last Updated: December 28, 2025, 11:32 am
Below is a detailed analysis of the quarterly data for Zota Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 104.00 Cr. (Jun 2025) to 129.00 Cr., marking an increase of 25.00 Cr..
- For Expenses, as of Sep 2025, the value is 123.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Jun 2025) to 123.00 Cr., marking an increase of 23.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Sep 2025, the value is 5.00%. The value appears strong and on an upward trend. It has increased from 4.00% (Jun 2025) to 5.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Jun 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 4.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -13.00 Cr. (Jun 2025) to -14.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 13.00%. The value appears to be increasing, which may not be favorable. It has increased from 5.00% (Jun 2025) to 13.00%, marking an increase of 8.00%.
- For Net Profit, as of Sep 2025, the value is -16.00 Cr.. The value appears to be declining and may need further review. It has decreased from -14.00 Cr. (Jun 2025) to -16.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -5.20. The value appears to be declining and may need further review. It has decreased from -4.81 (Jun 2025) to -5.20, marking a decrease of 0.39.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:22 am
| Metric | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 402 |
| Expenses | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 395 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | 7 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 5% | 1% | 11% | 5% | 4% | -2% | 2% |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 4 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 12 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 59 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | -0 | 12 | -5 | -16 | -58 | -60 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | -2% | |
| Net Profit | 2 | 2 | 3 | 4 | 6 | 3 | -0 | 9 | -6 | -14 | -57 | -62 |
| EPS in Rs | 2.17 | 1.43 | 1.85 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -19.70 | -21.29 |
| Dividend Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1,170% | 42% | -44% | -18% | -5% |
YoY Net Profit Growth
| Year | 2011-2012 | 2014-2015 | 2019-2020 | 2020-2021 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 33.33% | -50.00% | -100.00% | -166.67% | -133.33% | -307.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% | -83.33% | -50.00% | -66.67% | 33.33% | -173.81% |
Zota Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2011-2012 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| TTM: | 72% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -139% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 55% |
| 3 Years: | 72% |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -15% |
| 3 Years: | -24% |
| Last Year: | -36% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:15 am
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 29 | 31 |
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 195 | 285 |
| Borrowings | 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 140 | 181 |
| Other Liabilities | 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 76 | 109 |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 606 |
| Fixed Assets | 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 185 | 251 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 | 7 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 54 | 92 |
| Other Assets | 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 193 | 256 |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 606 |
Below is a detailed analysis of the balance sheet data for Zota Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 195.00 Cr. (Mar 2025) to 285.00 Cr., marking an increase of 90.00 Cr..
- For Borrowings, as of Sep 2025, the value is 181.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 140.00 Cr. (Mar 2025) to 181.00 Cr., marking an increase of 41.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 109.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Mar 2025) to 109.00 Cr., marking an increase of 33.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 606.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 439.00 Cr. (Mar 2025) to 606.00 Cr., marking an increase of 167.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 251.00 Cr.. The value appears strong and on an upward trend. It has increased from 185.00 Cr. (Mar 2025) to 251.00 Cr., marking an increase of 66.00 Cr..
- For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 92.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 38.00 Cr..
- For Other Assets, as of Sep 2025, the value is 256.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 256.00 Cr., marking an increase of 63.00 Cr..
- For Total Assets, as of Sep 2025, the value is 606.00 Cr.. The value appears strong and on an upward trend. It has increased from 439.00 Cr. (Mar 2025) to 606.00 Cr., marking an increase of 167.00 Cr..
Notably, the Reserves (285.00 Cr.) exceed the Borrowings (181.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -1.00 | 1.00 | 3.00 | 8.00 | 5.00 | 1.00 | 0.00 | -38.00 | -87.00 | -146.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 71 | 79 | 77 | 95 | 112 | 99 | 102 | 73 | 55 | 50 |
| Inventory Days | 122 | 141 | 134 | 175 | 208 | 139 | 140 | 121 | 183 | 201 | 281 |
| Days Payable | 77 | 90 | 0 | 0 | 104 | 82 | 77 | 78 | 116 | 126 | 113 |
| Cash Conversion Cycle | 120 | 123 | 212 | 251 | 199 | 169 | 161 | 145 | 140 | 131 | 219 |
| Working Capital Days | 102 | 70 | 78 | 80 | 175 | 152 | 143 | 108 | 111 | 75 | 100 |
| ROCE % | 20% | 32% | 6% | -2% | 15% | -2% | -7% | -17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -20.68 | -5.59 | -2.29 | 3.58 | -0.09 |
| Diluted EPS (Rs.) | -19.06 | -5.47 | -2.29 | 3.58 | -0.09 |
| Cash EPS (Rs.) | -4.73 | 2.22 | 2.46 | 5.00 | 1.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Revenue From Operations / Share (Rs.) | 102.31 | 69.83 | 55.63 | 52.14 | 43.48 |
| PBDIT / Share (Rs.) | -1.28 | 3.37 | 3.69 | 6.53 | 0.76 |
| PBIT / Share (Rs.) | -16.36 | -4.40 | -1.06 | 5.07 | -0.52 |
| PBT / Share (Rs.) | -20.13 | -6.25 | -1.86 | 4.94 | -0.14 |
| Net Profit / Share (Rs.) | -19.81 | -5.55 | -2.29 | 3.54 | -0.08 |
| NP After MI And SOA / Share (Rs.) | -19.70 | -5.55 | -2.29 | 3.54 | -0.08 |
| PBDIT Margin (%) | -1.25 | 4.82 | 6.63 | 12.52 | 1.76 |
| PBIT Margin (%) | -15.99 | -6.30 | -1.90 | 9.72 | -1.20 |
| PBT Margin (%) | -19.67 | -8.95 | -3.35 | 9.47 | -0.34 |
| Net Profit Margin (%) | -19.36 | -7.94 | -4.12 | 6.78 | -0.19 |
| NP After MI And SOA Margin (%) | -19.25 | -7.94 | -4.12 | 6.78 | -0.19 |
| Return on Networth / Equity (%) | -25.21 | -15.94 | -7.18 | 9.93 | -0.31 |
| Return on Capital Employeed (%) | -13.84 | -7.35 | -2.26 | 12.36 | -1.90 |
| Return On Assets (%) | -12.84 | -6.28 | -3.65 | 6.40 | -0.24 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.02 | 0.16 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.87 | 0.93 | 0.94 | 1.25 | 1.23 |
| Current Ratio (X) | 1.83 | 1.51 | 2.08 | 2.14 | 3.36 |
| Quick Ratio (X) | 0.77 | 0.78 | 1.05 | 1.33 | 1.81 |
| Inventory Turnover Ratio (X) | 0.20 | 0.26 | 0.49 | 0.71 | 0.75 |
| Dividend Payout Ratio (NP) (%) | 0.00 | -18.01 | -65.37 | 28.24 | -1175.68 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 45.05 | 61.02 | 20.00 | 82.97 |
| Earning Retention Ratio (%) | 0.00 | 118.01 | 165.37 | 71.76 | 1275.68 |
| Cash Earning Retention Ratio (%) | 0.00 | 54.95 | 38.98 | 80.00 | 17.03 |
| Interest Coverage Ratio (X) | -0.33 | 1.82 | 3.62 | 51.22 | 17.16 |
| Interest Coverage Ratio (Post Tax) (X) | -4.26 | -2.00 | -1.46 | 28.78 | -10.27 |
| Enterprise Value (Cr.) | 2311.57 | 1240.13 | 707.78 | 746.47 | 338.81 |
| EV / Net Operating Revenue (X) | 7.89 | 6.87 | 5.06 | 5.69 | 3.17 |
| EV / EBITDA (X) | -630.75 | 142.37 | 76.17 | 45.44 | 179.81 |
| MarketCap / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| Retention Ratios (%) | 0.00 | 118.01 | 165.37 | 71.75 | 1275.68 |
| Price / BV (X) | 10.31 | 13.63 | 8.82 | 8.35 | 5.13 |
| Price / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| EarningsYield | -0.02 | -0.01 | -0.01 | 0.01 | 0.00 |
After reviewing the key financial ratios for Zota Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -20.68. This value is below the healthy minimum of 5. It has decreased from -5.59 (Mar 24) to -20.68, marking a decrease of 15.09.
- For Diluted EPS (Rs.), as of Mar 25, the value is -19.06. This value is below the healthy minimum of 5. It has decreased from -5.47 (Mar 24) to -19.06, marking a decrease of 13.59.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.73. This value is below the healthy minimum of 3. It has decreased from 2.22 (Mar 24) to -4.73, marking a decrease of 6.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.31. It has increased from 69.83 (Mar 24) to 102.31, marking an increase of 32.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -1.28. This value is below the healthy minimum of 2. It has decreased from 3.37 (Mar 24) to -1.28, marking a decrease of 4.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is -16.36. This value is below the healthy minimum of 0. It has decreased from -4.40 (Mar 24) to -16.36, marking a decrease of 11.96.
- For PBT / Share (Rs.), as of Mar 25, the value is -20.13. This value is below the healthy minimum of 0. It has decreased from -6.25 (Mar 24) to -20.13, marking a decrease of 13.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -19.81. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.81, marking a decrease of 14.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -19.70. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.70, marking a decrease of 14.15.
- For PBDIT Margin (%), as of Mar 25, the value is -1.25. This value is below the healthy minimum of 10. It has decreased from 4.82 (Mar 24) to -1.25, marking a decrease of 6.07.
- For PBIT Margin (%), as of Mar 25, the value is -15.99. This value is below the healthy minimum of 10. It has decreased from -6.30 (Mar 24) to -15.99, marking a decrease of 9.69.
- For PBT Margin (%), as of Mar 25, the value is -19.67. This value is below the healthy minimum of 10. It has decreased from -8.95 (Mar 24) to -19.67, marking a decrease of 10.72.
- For Net Profit Margin (%), as of Mar 25, the value is -19.36. This value is below the healthy minimum of 5. It has decreased from -7.94 (Mar 24) to -19.36, marking a decrease of 11.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -19.25. This value is below the healthy minimum of 8. It has decreased from -7.94 (Mar 24) to -19.25, marking a decrease of 11.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is -25.21. This value is below the healthy minimum of 15. It has decreased from -15.94 (Mar 24) to -25.21, marking a decrease of 9.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is -13.84. This value is below the healthy minimum of 10. It has decreased from -7.35 (Mar 24) to -13.84, marking a decrease of 6.49.
- For Return On Assets (%), as of Mar 25, the value is -12.84. This value is below the healthy minimum of 5. It has decreased from -6.28 (Mar 24) to -12.84, marking a decrease of 6.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.02, marking a decrease of 0.14.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has decreased from 0.93 (Mar 24) to 0.87, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.83, marking an increase of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.77, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 4. It has decreased from 0.26 (Mar 24) to 0.20, marking a decrease of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -18.01 (Mar 24) to 0.00, marking an increase of 18.01.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 45.05 (Mar 24) to 0.00, marking a decrease of 45.05.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 118.01 (Mar 24) to 0.00, marking a decrease of 118.01.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 54.95 (Mar 24) to 0.00, marking a decrease of 54.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.33. This value is below the healthy minimum of 3. It has decreased from 1.82 (Mar 24) to -0.33, marking a decrease of 2.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -4.26. This value is below the healthy minimum of 3. It has decreased from -2.00 (Mar 24) to -4.26, marking a decrease of 2.26.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,311.57. It has increased from 1,240.13 (Mar 24) to 2,311.57, marking an increase of 1,071.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 3. It has increased from 6.87 (Mar 24) to 7.89, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is -630.75. This value is below the healthy minimum of 5. It has decreased from 142.37 (Mar 24) to -630.75, marking a decrease of 773.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 118.01 (Mar 24) to 0.00, marking a decrease of 118.01.
- For Price / BV (X), as of Mar 25, the value is 10.31. This value exceeds the healthy maximum of 3. It has decreased from 13.63 (Mar 24) to 10.31, marking a decrease of 3.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 24) to -0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zota Health Care Ltd:
- Net Profit Margin: -19.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -13.84% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -25.21% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -4.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -19.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Zota House, 2/896, Surat Gujarat 395002 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ketankumar Chandulal Zota | Non Executive Chairman |
| Mr. Moxesh Ketanbhai Zota | Managing Director |
| Mr. Laxmi Kant Sharma | Executive Director |
| Mr. Himanshu Muktilal Zota | Whole Time Director |
| Mr. Kamlesh Rajnikant Zota | Whole Time Director |
| Mr. Viren Manukant Zota | Whole Time Director |
| Mrs. Jaysheeben Nileshkumar Mehta | Ind. Non-Executive Director |
| Mrs. Bhumi Maulik Doshi | Ind. Non-Executive Director |
| Dr.(Mrs.) Varsaben Gaurang Mehta | Ind. Non-Executive Director |
| CA. Dhaval Chandubhai Patwa | Ind. Non-Executive Director |
| CA. Vitrag Sureshkumar Modi | Ind. Non-Executive Director |
| Dr. Dhiren Prafulbhai Shah | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Zota Health Care Ltd?
Zota Health Care Ltd's intrinsic value (as of 28 December 2025) is 445.27 which is 71.03% lower the current market price of 1,537.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 5,097 Cr. market cap, FY2025-2026 high/low of 1,740/752, reserves of ₹285 Cr, and liabilities of 606 Cr.
What is the Market Cap of Zota Health Care Ltd?
The Market Cap of Zota Health Care Ltd is 5,097 Cr..
What is the current Stock Price of Zota Health Care Ltd as on 28 December 2025?
The current stock price of Zota Health Care Ltd as on 28 December 2025 is 1,537.
What is the High / Low of Zota Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zota Health Care Ltd stocks is 1,740/752.
What is the Stock P/E of Zota Health Care Ltd?
The Stock P/E of Zota Health Care Ltd is .
What is the Book Value of Zota Health Care Ltd?
The Book Value of Zota Health Care Ltd is 103.
What is the Dividend Yield of Zota Health Care Ltd?
The Dividend Yield of Zota Health Care Ltd is 0.07 %.
What is the ROCE of Zota Health Care Ltd?
The ROCE of Zota Health Care Ltd is 17.0 %.
What is the ROE of Zota Health Care Ltd?
The ROE of Zota Health Care Ltd is 36.0 %.
What is the Face Value of Zota Health Care Ltd?
The Face Value of Zota Health Care Ltd is 10.0.